CHMP gives positive opinions for new drugs from GSK, Roche & SpringWorks, including GSK's Blenrep, Roche's Itovebi & ...

President Donald Trump unofficially asked CMS Administrator Mehmet Oz to lead the administration’s talks with drugmakers to ...

Nearly one out of every 20 staff in the FDA offices that oversee drugs and biologics are gone after the Trump administration ...

The Trump administration has been barred from carrying out its sweeping plan to restructure and downsize the Department of ...

Volastra reports promising Phase 1/2 data for VLS-1488 in solid tumors, with good safety and early efficacy signals in ...

Geoffrey Porges, a longtime biotech analyst and well-known Wall Street figure, stepped down as CFO of the New York biotech ...

Merus completed its rollout of Phase 2 head and neck cancer data on Thursday, touting overall survival results that at least ...

Cigna on Wednesday said it negotiated with Novo Nordisk and Eli Lilly to secure deeper GLP-1 drug discounts for employers ...

Sanofi will acquire Vigil for its oral small molecule TREM2 project, dubbed VG-3927, that is on tap for a Phase 2 in ...

Beam Therapeutics CEO John Evans warns against AI hype in drug development, drawing parallels to past CRISPR expectations, ...

Jazz's Zepzelca + Roche's Tecentriq shows 27% reduced death risk & improved survival in lung cancer trial; FDA application ...

Hinge Health prices IPO at $32/share, valuing company at $3B. CEO Daniel Perez's firm to trade as HNGE on NYSE, raising ...